Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Auriga Laboratories has reported FDA approval of Liquadd oral solution 5mg/5mL indicated for the treatment of attention deficit disorder with hyperactivity or ADHD.
Subscribe to our email newsletter
The company has said that Liquadd will be launched during the second quarter of 2008.
Frank Greico, CEO of Auriga, said: “This new product further solidifies company’s commitment to enhance our product portfolio. Currently, we promote several of our products to psychiatrists and pediatricians, and Liquadd will be a highly synergistic addition to company’s current promotional efforts in these specialties.”